We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
To ensure best performance, routine calibration is required using fingerstick readings from a blood glucose meter. DO NOT use alternative test sites such as your forearm when entering BG values for calibration. Any commercially available meter may be used for calibration. Once your sensor has been inserted and linked to your smart transmitter, the system begins a 24-hour Warm-Up Phase. No calibration is required during this phase.
There are three calibration phases:
Initialization Phase – After the 24-hour Warm-Up Phase, you must complete 4 fingerstick calibrations, spaced 2 to 12 hours apart.
2 Daily Calibrations Phase – After the Initialization Phase, you must complete a fingerstick calibration every 12 hours for at least 21 days.
1 Daily Calibration Phase – The system will detect if 1 or 2 daily calibrations are needed and will alert you. In the 1 Daily Calibration Phase, you must complete a fingerstick calibration every 24 hours.
No. If the algorithm determines 2 calibrations/day are needed to maintain the most accurate readings possible, the user will be notified. The best way for a user to support system accuracy is to calibrate as prompted and to always calibrate the system using only a fingerstick blood sample. DO NOT calibrate at times when glucose may be rapidly changing (e.g., after meals, after dosing insulin). DO NOT use a blood glucose reading from an alternative site (such as forearm or palm) to calibrate the system.
No, however data from the clinical study showed all users were prompted to switch to 1 calibrations/day for the first time within about 10 days after day 21.
The Eversense® E3 CGM System measures glucose in interstitial fluid (ISF) between the body’s cells.Physiologic differences between ISF and blood from a finger stick may result in differences in glucose measurements. These differences are especially evident during times of rapid change in blood glucose (e.g., after eating, dosing insulin, or exercising). On average, glucose levels in ISF lag behind glucose levels in blood by several minutes.
The trend arrow on the My Glucose screen of the Eversense® App screen will give you an indication of which direction the glucose is moving towards, up or down and the rate of change.
Sensor: The sensor is considered medical waste and will be disposed of by your health care professional.
Transmitter: The transmitter contains a reusable battery and should be disposed of based on your local regulations.
Adhesive patch: The adhesive patch can be thrown away with normal household trash.
To clean your smart transmitter, wipe it down with a water dampened cloth. Reuse after drying completely.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060